MX2023010899A - Administracion ocular de agentes terapeuticos. - Google Patents

Administracion ocular de agentes terapeuticos.

Info

Publication number
MX2023010899A
MX2023010899A MX2023010899A MX2023010899A MX2023010899A MX 2023010899 A MX2023010899 A MX 2023010899A MX 2023010899 A MX2023010899 A MX 2023010899A MX 2023010899 A MX2023010899 A MX 2023010899A MX 2023010899 A MX2023010899 A MX 2023010899A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
methods
ocular delivery
devices
ocular
Prior art date
Application number
MX2023010899A
Other languages
English (en)
Inventor
Robert Farra
Jaka Cemazar
Gayathri Ramaswamy
Cathleen Gonzales
Rosario Fernandez-Godino
Original Assignee
Intergalactic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intergalactic Therapeutic Inc filed Critical Intergalactic Therapeutic Inc
Publication of MX2023010899A publication Critical patent/MX2023010899A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/0436—Material of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0543—Retinal electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención involucra dispositivos y terapias para enfermedades o trastornos oculares en individuos. En este documento se proporcionan agentes terapéuticos, y dispositivos y métodos para administrar agentes terapéuticos (por ejemplo, vectores de ácido nucleico) a células oculares objetivo (por ejemplo, células retinianas) que involucran métodos para administrar agentes terapéuticos al individuo y métodos de electrotransferencia de agentes terapéuticos.
MX2023010899A 2021-03-19 2022-03-21 Administracion ocular de agentes terapeuticos. MX2023010899A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163163350P 2021-03-19 2021-03-19
US202163167437P 2021-03-29 2021-03-29
US202163167296P 2021-03-29 2021-03-29
US202163167463P 2021-03-29 2021-03-29
US202163293297P 2021-12-23 2021-12-23
US202263316699P 2022-03-04 2022-03-04
PCT/US2022/021209 WO2022198138A1 (en) 2021-03-19 2022-03-21 Ocular delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
MX2023010899A true MX2023010899A (es) 2024-02-12

Family

ID=83320931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010899A MX2023010899A (es) 2021-03-19 2022-03-21 Administracion ocular de agentes terapeuticos.

Country Status (9)

Country Link
US (2) US20220305142A1 (es)
EP (1) EP4308708A1 (es)
JP (1) JP2024512520A (es)
KR (1) KR20240019755A (es)
AU (1) AU2022238492A1 (es)
CA (1) CA3212469A1 (es)
IL (1) IL306009A (es)
MX (1) MX2023010899A (es)
WO (1) WO2022198138A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024168210A1 (en) * 2023-02-10 2024-08-15 Aldevron, Llc Gene therapies for the front of the eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
WO2014141197A1 (en) * 2013-03-14 2014-09-18 Baylis Medical Company Inc. Electrosurgical device having a lumen
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
JP7371083B2 (ja) * 2018-07-20 2023-10-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 遺伝子治療発現ベクターの眼内送達

Also Published As

Publication number Publication date
AU2022238492A1 (en) 2023-10-05
CA3212469A1 (en) 2022-09-22
US20220305142A1 (en) 2022-09-29
EP4308708A1 (en) 2024-01-24
WO2022198138A8 (en) 2023-04-27
AU2022238492A9 (en) 2024-02-22
IL306009A (en) 2023-11-01
US20240156638A1 (en) 2024-05-16
KR20240019755A (ko) 2024-02-14
JP2024512520A (ja) 2024-03-19
WO2022198138A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US11911610B2 (en) Methods for restoring sensitivity to TTFields in TTFields-resistant cancer cells with PTGER3 inhibitors
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2020008274A (es) Metodos y composiciones para la administracion de proteinas terapeuticas.
MX2020003945A (es) Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
MX2020012077A (es) Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
WO2009073527A3 (en) Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2022056266A8 (en) Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
EP4282472A3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
BR112019004353A2 (pt) métodos e vetores para tratar distúrbios do cns
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2023010899A (es) Administracion ocular de agentes terapeuticos.
WO2022040641A3 (en) Functional ionizable phospholipids
MX2022003134A (es) Administracion intranasal de esketamina.
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
Ortega et al. Restorative therapies to enhance sensorimotor recovery following cerebral ischemia
AR118696A1 (es) Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
Salvinelli et al. Enhanced presence of NGF and mast cells number in nasal cavity after autologous stimulation: relation with sensorineural hearing deficit.
MX2020005809A (es) Composicion topica oftalmica para tratar enfermedades del segmento posterior del ojo.
MX2011012659A (es) Terapia con vacunas para neovascularizacion coroidea.
SG11201906820WA (en) Erythropoietin-derived peptide, preparation method therefor, and use thereof
EP4151210A3 (en) Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
WO2020100089A3 (en) Compositions and methods for the treatment of smooth muscle dysfunction